Back to top
more

Blueprint Medicines (BPMC)

(Delayed Data from NSDQ)

$93.36 USD

93.36
578,082

+0.54 (0.58%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $93.34 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Blueprint Medicines (BPMC) Down 2% Since Last Earnings Report?

by Zacks Equity Research

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.

Blueprint Medicines (BPMC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Blueprint Medicines (BPMC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 15.12% and 27.94%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up

by Zacks Equity Research

Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.

Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 19.17% and 48.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Blueprint Medicines (BPMC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Horizon Therapeutics (HZNP) Down 0.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Editas (EDIT) Down 21% Since Last Earnings Report?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use

by Zacks Equity Research

The FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. Stock up on Tuesday in response.

Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up

by Zacks Equity Research

Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.

Biotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer Updates

by Zacks Equity Research

Earnings results from Biogen (BIIB) and updates from EBS are the key highlights from the biotech sector during the past week.

Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.93% and 18.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others

by Zacks Equity Research

Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.

Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA

by Zacks Equity Research

Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Blueprint Medicines (BPMC) Climb 61.38% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 61.4% in Blueprint Medicines (BPMC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Blueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority Tag

by Zacks Equity Research

The FDA accepts and grants priority review to Blueprint Medicines' (BPMC) sNDA for the label expansion of Aykavit for indolent systemic mastocytosis.

Deciphera (DCPH) Rises 70% in the Past 6 Months: Here's Why

by Zacks Equity Research

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

ADC Therapeutics SA (ADCT) Stock Jumps 21.8%: Will It Continue to Soar?

by Zacks Equity Research

ADC Therapeutics SA (ADCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Strength Seen in Fate Therapeutics (FATE): Can Its 9.3% Jump Turn into More Strength?

by Zacks Equity Research

Fate Therapeutics (FATE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Apellis Pharmaceuticals, Inc. (APLS) Down 0.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.